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Abstract
Background: Patient-reported outcome (PROs) measures are being used more frequently in
investigational studies of treatments for moderate to severe plaque psoriasis. The objective of this
study was to examine the relationships among the Dermatology Life Quality Index (DLQI), the
Short Form 36 (SF-36), and the EuroQOL 5D (EQ-5D) and to assess their validity, responsiveness,
and estimates of minimum important differences.
Methods: A Phase II, randomized, double-blind, parallel group, placebo-controlled, multi-center
clinical trial assessed the clinical efficacy and safety of two doses of subcutaneously administered
adalimumab vs. placebo for 12 weeks in the treatment of 147 patients with moderate to severe
plaque psoriasis. This study provided the opportunity to evaluate the validity and responsiveness
to change in clinical status of PROs instruments. Patients completed the DLQI, SF-36, and EQ-5D
questionnaires at baseline and at 12 weeks. Blinded investigators assessed the Psoriasis Area and
Severity Index (PASI) scores and the Physician's Global Assessment (PGA) scores of enrolled
patients. The responsiveness of the measures to changes in the clinical endpoints from baseline to
Week 12 was assessed. Estimates of minimum important differences (MID) were derived. All
analyses were performed with blinded data; findings and conclusions were not biased based on
treatment condition.
Results: The dermatology-specific DLQI was highly correlated to clinical endpoints at baseline and
at Week 12, and was the most responsive PRO to changes in endpoints. Compared with the SF-
36, the EQ-5D index score and VAS scores were generally more highly correlated with clinical
endpoints, but displayed about the same degree of responsiveness. The most responsive SF-36
scales were the Bodily Pain and Social Functioning scales. Estimates of the MID for the DLQI ranged
from 2.3–5.7 and for the SF-36 Physical Component Summary (PCS) score ranged from 2.5–3.9.
Conclusion: This study provides support for the continued use of the DLQI and SF-36 PCS in the
assessment of treatments for psoriasis. On the basis of the results from this trial, the EQ-5D should
be considered as a general PRO measure in future clinical trials of patients with moderate to severe
plaque psoriasis.
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Background
Moderate to severe plaque psoriasis has been demon-
strated to have substantial impact on function limitations
and psychosocial factors of patients with the disease [1-5].
Moreover, successful treatment of moderate to severe pso-
riasis – as assessed by improved physical functioning and
reduction of signs and symptoms – has been shown to
have a positive impact on social and psychological aspects
of psoriasis [6-11].
Given the functional and psychosocial impact of the dis-
ease, studies of moderate to severe psoriasis patients often
include both physician-assessed clinical endpoints and
dermatology-specific patient-reported outcomes (PROs)
to obtain a holistic view of the disease and treatment
effects in patients [12]. Such practices are bolstered by the
assertion of the Medical Advisory Board of the National
Psoriasis Foundation (NPF) that, even more so than phys-
ical signs, such as the percentage of body surface area
(BSA) affected by psoriasis, the severity of psoriasis is "first
and foremost a quality-of-life (QOL) issue" [13]. The
same values for percentage BSA involvement can result in
very different degrees of impact for different patients,
depending on the location of psoriatic plaques, the pain
associated with the lesions and plaques, the extent of
bleeding associated with the psoriatic lesions, and result-
ing functional limitations. The NPF Advisory Board sug-
gests an alternative basis for defining mild, moderate, or
severe psoriasis, predicated on QOL impacts of the dis-
ease. Similarly, the guidelines recently promulgated by the
British Association of Dermatologists [14] for the use of
biologics in psoriasis indicate that eligible patients must
have a Psoriasis Area and Severity Index (PASI) score of at
least 10 and a score on the Dermatology Life Quality
Index (DLQI) [15] – a dermatology-specific validated
PRO measure – of greater than 10.
A Phase II clinical trial of two dosages of adalimumab and
placebo in the treatment of moderate to severe psoriasis
provided an opportunity to further explore the psycho-
metric characteristics – including responsiveness and min-
imum important differences – of the three PROs used in
the trial: the DLQI; the general health-related QOL meas-
ure MOS Short Form 36 (SF-36) Health Survey [16]; and
the general health status measure EuroQOL 5D (EQ-5D)
[17,18]. Establishing the reliability, validity, and respon-
siveness of PRO measures is necessary for their use in sup-
port of labeling claims, according to an FDA draft guide to
industry [19]. Reliability refers to the accuracy of a meas-
ure, while validity refers to the extent the measure actually
is measuring what it purports to measure. Responsiveness
is a component of validity and represents the PRO's capa-
bility to detect changes related to changes in the clinical
status of patients or other relevant outcomes measures.
Minimum important difference (MID) is related to
responsiveness and provides guidance to those reviewing
clinical trial results as to whether the statistically signifi-
cant group differences or changes are clinically meaning-
ful and important. Jaeschke and colleagues [20] define a
minimal clinically important difference (MCID) (we use
MID instead of MCID to avoid confusion) as "the smallest
difference in score ... which patients perceive as beneficial
and which would mandate, in the absence of troublesome
side-effects and excessive cost, a change in the patient's
management." Estimation of the MID – using several dif-
ferent approaches – is also emphasized in the FDA guid-
ance and is consistent with recently published
recommendations of health outcomes researchers
[21,22].
Methods
Overview
The objectives of the Phase II, randomized, double-blind,
parallel group, placebo-controlled, multi-center clinical
trial were to assess the clinical efficacy and safety of sub-
cutaneously administered adalimumab vs. placebo using
two dosage regimens for 12 weeks in the treatment of 147
patients with moderate to severe plaque psoriasis. The
study included a screening period, a blinded 12-week
treatment period, and a 30-day follow-up visit for patients
not completing 12 weeks of active treatment or not enter-
ing an extension study. Time between screening and base-
line visits was not to exceed 28 days. The trial achieved the
objectives of the study in terms of safety and clinical effi-
cacy endpoints [23].
Patients and inclusion criteria
Patients with a diagnosis of moderate to severe plaque
psoriasis and an affected BSA of ≥ 5% for at least 1 year
were eligible for the study. In addition to other inclusion
criteria (e.g., age ≥ 18 years, willingness to give informed
consent), patients had to be able to self-inject medication
or have a designee or nurse who could inject the rand-
omized assignment. Patients signed informed consent
forms, and the study complied with FDA Good Clinical
Practices, Health Protection Branch guidelines, and all
other applicable ethical, legal, and regulatory require-
ments [23].
Clinical measures
For purposes of the analyses reported here, there were two
primary clinical outcomes:
Psoriasis Area and Severity Index
Frequently used as an endpoint in psoriasis clinical trials
[24], the PASI [25] was the primary efficacy outcome in
this trial. PASI is a composite index indicating the severity
of the three main signs of psoriatic plaques (i.e., ery-
thema, scaling, and thickness) and is weighted by the
amount of coverage of these plaques in the four mainHealth and Quality of Life Outcomes 2006, 4:71 http://www.hqlo.com/content/4/1/71
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body areas (head, trunk, upper extremities, and lower
extremities). PASI scores range from 0–72, with higher
scores indicating greater disease severity. PASI was
assessed at screening and baseline, at Weeks 1, 2, 4, 8, and
12/Early Termination, and at the final follow-up visit.
Physician's Global Assessment
The PGA is a seven-point scale used to measure the sever-
ity of disease at the time of the physician's evaluation. The
seven disease categories are:
￿ Severe: very marked plaque elevation, scaling, and/or
erythema
￿ Moderate to Severe: marked plaque elevation, scaling,
and/or erythema
￿ Moderate: moderate plaque elevation, scaling, and/or
erythema
￿ Mild to moderate: intermediate between moderate and
mild
￿ Mild: slight plaque elevation, scaling, and/or erythema
￿ Almost Clear: intermediate between mild and clear
￿ Clear: no signs of psoriasis (post-inflammatory hypopig-
mentation or hyperpigmentation could be present).
The PGA scale is scored from 1 (Clear) to 7 (Severe). The
PGA was assessed by the investigator at screening, base-
line, and Weeks 1, 2, 4, 8, 12/Early Termination, and the
follow-up visit. Each study site was to make every attempt
to have the same investigator perform these assessments
throughout the study for each patient.
Patient-Reported Outcome measures
Three PROs measures were used in the study and are the
subject of the analyses reported here. All PROs measures
were assessed at baseline and at Week 12 (or early termi-
nation, if applicable).
Dermatology Life Quality Index
The DLQI was developed as a simple, compact, and prac-
tical questionnaire for use in dermatology clinical settings
to assess limitations related to the impact of skin disease
[15]. The instrument contains 10 items dealing with skin
(e.g., Item 1: "Over the last week, how itchy sore, painful,
or stinging has your skin been?"). The DLQI score ranges
from 0–30, with "30" corresponding to the worst quality
of life, and "0" corresponding to the best score. The DLQI
has well-established properties of reliability and validity
in the dermatology setting [15,26-28].
Short Form 36 health survey
The SF-36 is a 36-item general health status instrument
often used in clinical trials and health services research
[16]. It consists of eight domains: Physical Function, Role
Limitations-Physical, Vitality, General Health Percep-
tions, Bodily Pain, Social Function, Role Limitations –
Emotional, and Mental Health. Two overall summary
scores can be obtained – a Physical Component Summary
(PCS) score and a Mental Component Summary (MCS)
score [29]. The PCS and MCS scores range from 0–100,
with higher scores indicating better health. The SF-36 has
been used in a wide variety of studies involving psoriasis,
including descriptive studies [30] and clinical research
studies [6,7], and has demonstrated good reliability and
validity. Internal consistency for most SF-36 domains is
greater than 0.70. The SF-36 has been shown to discrimi-
nate between known groups in a variety of diseases, is
reproducible, and is responsive to longitudinal clinical
changes.
EuroQOL 5D
The EQ-5D [17,18] is a six-item, preference-based instru-
ment designed to measure general health status. The EQ-
5D has two sections: The first consists of five items to
assess degree of physical functioning (mobility, self-care,
usual activities, pain/discomfort, and anxiety/depres-
sion). Items are rated on a three-point scale ranging from
"No Problem" to "Extreme Problem" or "Unable to Do."
Each pattern of scores for the five items is linked to an
index score that has a value ranging from 0–1, indicating
the health utility of that person's health status. The spe-
cific linkage can differ from country to country, reflecting
differences in cultures to the item responses. The second
section is the sixth item on the EQ-5D, which is a visual
analog scale with endpoints of "100" or "Best Imaginable
Health," and "0" or "Worst Imaginable Health." It offers a
simple method for the respondents to indicate how good
or bad their health statuses are "today." The score is taken
directly from the patients' responses.
Statistical methods
Validity of the PRO measures was assessed in several ways.
First, an assessment was made of the concurrent validity of
scales and subscales (i.e., the extent to which PRO meas-
ures are correlated with one another). As a disease-specific
PRO measure, the DLQI was expected to correlate moder-
ately to extremely well with general PRO measures.
Another important aspect of validity in this study was to
assess the extent to which the PRO measures correlated
with the clinical endpoints – PASI and PGA – both at base-
line and at Week 12.
Responsiveness of PRO measures was assessed via two
approaches. First, changes in these measures from base-
line to Week 12 were correlated with changes in the PASIHealth and Quality of Life Outcomes 2006, 4:71 http://www.hqlo.com/content/4/1/71
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or PGA over the 12-week course of treatment within the
trial. Concurrent improvement in both clinical measures
and PRO measures was expected to result in positive cor-
relations. The second approach to assessing responsive-
ness involved categorizing patients into responder groups
based on the changes in their PASI scores from baseline to
Week 12. This was done in two ways. First, a responder
was defined as a patient with >75% improvement in PASI
(consistent with the definition of success with the primary
efficacy variable), and a non-responder was defined as a
patient with a PASI improvement <50% (consistent with
the definition of failure for a secondary efficacy variable).
Tests of mean differences in improvement on the PRO
measures were completed between the two groups. Sec-
ondly, in support of the estimation of the MID, discussed
below, patients were further categorized by degree of PASI
response, and assessed differences among these four
groups: PASI improvement <25%; PASI improvement 25–
49%; PASI improvement 50–74%; and PASI improve-
ment ≥ 75%. Analyses of variance tests were performed
among these four groups for changes in PRO measures.
In accordance with the FDA draft guidance [19] and con-
sistent with recent recommendations from PRO research-
ers [21,22], five methods were used to estimate MIDs of
the PROs. The PRO change score corresponding to PASI
25-PASI 49 was the first estimate of MID, called MID-1.
This was based on the assumption that patients would
perceive a PASI improvement of 25% as beneficial. The
trial did not provide data to test this assumption (e.g.,
there was no rating by patients of their overall improve-
ments). A second estimate, MID-2, was based on the PRO
change score corresponding to a PASI improvement
between 50–74%. The PASI 50 is seen as clinically rele-
vant, and, as such, this degree of improvement served as a
secondary efficacy endpoint in this trial. A third method
for estimating MID relied on the association of changes in
the PRO measure with changes in the PGA. A non-
responder was defined as a patient with a PGA change
score of either "0" (no change) or "1" (slight increase in
severity of disease) from baseline to Week 12. A minimal
responder was defined as a patient whose PGA improved
by either 1 or 2 points from baseline to Week 12. The third
estimate of MID, MID-3, was the difference in the PRO
score between non-responders and minimal responders.
In addition, two distributional methods were used to sup-
port the anchor-based MID estimates for the PROs
[21,22]. Based on evidence by Wyrwich and associates
[31,32], the standard error of measurement (SEM) can be
used to approximate the MID. The SEM, which describes
the error associated with the measure, was estimated by
the standard deviation of the measure multiplied by the
square root of 1 minus its reliability coefficient. Finally,
there has been discussion [33] concerning a number of
studies demonstrating that one-half of the standard devi-
ation of a measure represents the upper limit of the MID
[22]. In estimating the SEM for the SF-36 and the EQ-5D,
reliability estimates from the literature were used. The
SEM for the DLQI incorporated the reliability estimated
from the trial data, which was consistent with what has
been found in the literature for this instrument [27].
Finally, it is important to note that all analyses were per-
formed with blinded data (i.e., the statuses of patients
with respect to their assigned treatment groups were not
known).
Results
Patient demographics and clinical characteristics
A total of 147 patients enrolled and received at least one
dose of study medication at 18 sites in the United States
and Canada. Blinded data were available for the PROs for
147 patients at baseline and 140 patients at Week 12.
Since the focus of these analyses were on the psychometric
properties of the PROs rather than with efficacy, observed
cases were employed rather than last observation carried
forward or other methods for treating missing observa-
tions at the end of trial. The mean age of the patients
enrolled in the trial was 44.2 years, two-thirds were male,
and the preponderance were white (Table 1).
Clinical endpoints
The results for the PASI and the PGA at baseline and Week
12, as well as the change from baseline to Week 12, are
displayed in Table 2. The mean PASI at baseline was 15.7,
which decreased by 8.9 points (improvement) to 6.8 by
Week 12. The mean PGA at baseline was 5.5 (i.e., midway
between "Moderate" and "Moderate to Severe"), and
decreased (improved) by 2.1 points to 3.4 by Week 12
(i.e., between "Mild" and "Mild to Moderate"). In evalu-
ating the improvement in the two clinical endpoints, it is
important to keep in mind that these analyses included
pooled placebo and active treatment groups.
Table 1: Baseline demographic characteristics
Characteristic (N = 147)
Age
Mean (SD) 44.2 (12.7)
Gender
Female n (%) 48 (32.7%)
Male n (%) 99 (67.3%)
Race
White n (%) 133 (90.5%)
Black n (%) 4 (2.7%)
Asian n (%) 5 (3.4%)
Other n (%) 5 (3.4%)Health and Quality of Life Outcomes 2006, 4:71 http://www.hqlo.com/content/4/1/71
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Patient-Reported Outcome measures
The results for the DLQI, SF-36, and EQ-5D at baseline
and Week 12, and the change from baseline are shown in
Table 3. Based on blinded data, mean PRO measures
improved during the course of the trial (a decrease in
DLQI scores indicates an improvement; an increase in the
SF-36 and EQ-5D indicates improvement). The greatest
improvement in a DLQI item occurred for the first item,
assessing how "itchy, sore, painful, or stinging" the per-
son's skin felt (data not shown). Similarly, as shown in
Table 3, the greatest improvement among the SF-36 scales
was for Bodily Pain. The largest improvement among the
five EQ-5D dimensions occurred for the Pain/Discomfort
dimension (data not shown). Given these findings, it
appears that improvement in pain and discomfort is the
most pronounced among all PRO measures assessed.
The reliability of the DLQI, as assessed by coefficient
alpha, was 0.89 at baseline and 0.92 at Week 12, indicat-
ing that this is a highly reliable measure, and in line with
previous findings [27,28].
Relationships among Patient-Reported Outcome 
measures
Table 4 displays the correlations among PRO measures at
baseline and at Week 12, as well as the correlations among
changes in these measures from baseline to Week 12.
There were a few trends evident form this data. First, all
measures were statistically significantly inter-correlated.
Second, with respect to the relationship between the
DLQI and the SF-36, the DLQI correlated the greatest with
the Bodily Pain and Social Functioning domains, both at
baseline and at Week 12, and, for changes in these scores
over the course of the trial. Third, the DLQI correlated
highly with the EQ-5D index score, and these correlations
were consistently higher than the correlations with the
EQ-5D visual analog scale (VAS) scores. Fourth, the EQ-
5D index score tended to correlate greatest with the Bodily
Pain domain of the SF-36. Finally, the scores tended to be
more highly correlated at the end of the trial than at base-
line, consistent with previous findings [28].
Correlations with clinical endpoints
Table 5 displays correlations of PRO measures with the
two clinical assessments – PASI score and PGA – at base-
line (first two columns of data) and at Week 12 (second
two columns). In addition to almost uniformly greater
correlations at Week 12 vs. at baseline – consistent with
previous findings [28] – one can also note that both the
DLQI and EQ-5D index score tended to be more highly
correlated with the two clinical endpoints than any of the
SF-36 domains. The SF-36 scales with the strongest associ-
Table 2: Mean (Standard Deviation) of PASI and PGA at baseline and week 12, and change from baseline to week 12
Measure Baseline Week 12 Change2
PASI 15.69 (7.34) 6.84 (7.77) -8.87 (8.41)
PGA1 5.48 (0.81) 3.36 (1.74) -2.14 (1.87)
1 Scored such that 1 = "Clear" to 7 = "Severe."
2Change scores are computed only for the 140 patients with scores at baseline and Week 12; sample size at baseline = 147.
Table 3: Mean (Standard Deviation) of PROs at baseline and week 12, and change from baseline to week 12
Measure Baseline Week 12 Change1
DLQI Total Score 12.71 (7.18) 5.28 (6.49) -7.45 (7.78)
SF-36
Physical Functioning 79.26 (24.95) 84.43 (22.62) 5.63 (22.25)
Role-Physical 72.45 (37.56) 82.50 (34.67) 9.64 (40.30)
Bodily Pain 59.58 (25.37) 75.87 (24.89) 16.59 (26.90)
General Health 66.7 (20.6) 72.69 (20.79) 6.10 (16.25)
Vitality 53.89 (22.81) 61.04 (23.18) 7.60 (20.88)
Social Functioning 74.49 (27.56) 85.98 (23.63) 11.16 (27.80)
Role-Emotional 76.03 (35.39) 85.48 (30.77) 8.39 (37.02)
Mental Health 69.39 (19.30) 77.43 (17.73) 8.14 (18.57)
Physical Summary Score (PCS) 47.93 (10.23) 51.24 (9.51) 3.47 (9.30)
Mental Summary Score (MCS) 47.30 (11.23) 51.36 (10.08) 3.94 (11.04)
EQ-5D
Index Score 0.66 (0.28) 0.82 (0.23) 0.16 (0.29)
VAS Overall Health 72.25 (20.67) 81.22 (17.26) 9.35 (20.71)
1Change scores are computed only for patients with scores at baseline and Week 12; this number varied between 138 and 140, depending on the 
specific measure, as compared with the 147 patients at baseline.Health and Quality of Life Outcomes 2006, 4:71 http://www.hqlo.com/content/4/1/71
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ation with clinical endpoints are Social Functioning and
Bodily Pain.
Responsiveness of the Patient-Reported Outcome 
measures
An important attribute for a PRO measure is responsive-
ness to change in the clinical status of a patient (i.e., as a
patient's disease improves, the PRO measures also
improve). The last two columns of Table 5 display the cor-
relations between changes in PRO measures used in the
trial and changes in PASI scores and the PGA from base-
line to Week 12. These data demonstrate that the DLQI is
the most responsive of the PRO measures. The correla-
tions between changes over the course of the trial in the
DLQI total score and changes in the PASI score (r = 0.69,
p < 0.001) and PGA (r = 0.71, p < 0.001) approach the
correlation between changes in the two clinical measures
themselves (r = 0.75, p < 0.001). In addition, the DLQI is
the only one of the PRO measures to demonstrate equal
responsiveness to PGA and PASI scores. The correlation
between changes in the EQ-5D index score and the two
clinical assessments was r = -0.57 (p < 0.001) for changes
in the PASI to r = -0.44 for changes in the PGA (p < 0.001).
Similarly, the correlations between changes in all but one
of the SF-36 scores and changes in the PGA were smaller
than correlations between changes in the SF-36 and the
PASI.
A second way to assess responsiveness was to contrast
patients who were defined as clinical responders with
those characterized as non-responders. Given that the pri-
mary endpoint in the trial was defined as the percentage
of patients achieving a PASI 75 response (i.e., ≥ 75%
improvement in PASI from. baseline) by Week 12, a
Table 4: Correlations1 among PROs at baseline and week 12, and change from baseline to week 12
Measure Baseline Week 12 Change
DLQI 
Total
EQ-5D 
Index
EQ-5D 
VAS
DLQI 
Total
EQ-5D 
Index
EQ-5D 
VAS
DLQI 
Total
EQ-5D 
Index
EQ-5D 
VAS
DLQI 
Total 
Score
1.00 -0.51 -0.35 1.00 -0.71 -0.58 1.00 -0.53 -0.46
SF-36
Physical 
Functioni
ng
-0.44 0.58 0.35 -0.41 0.61 0.49 -0.29 0.47 0.32
Role-
Physical
-0.45 0.64 0.38 -0.57 0.67 0.50 -0.47 0.51 0.45
Bodily 
Pain
-0.55 0.73 0.45 -0.61 0.76 0.56 -0.66 0.64 0.53
General 
Health
-0.24** 0.39 0.47 -0.38 0.59 0.69 -0.33 0.46 0.46
Vitality -0.31 0.43 0.48 -0.43 0.62 0.60 -0.46 0.37 0.48
Social 
Functioni
ng
-0.69 0.52 0.46 -0.68 0.74 0.60 -0.68 0.50 0.56
Role-
Emotiona
l
-0.41 0.45 0.42 -0.56 0.67 0.53 -0.50 0.41 0.48
Mental 
Health
-0.44 0.46 0.50 -0.56 0.66 0.67 -0.52 0.49 0.56
Physical 
Summary 
Score 
(PCS)
-0.41 0.64 0.36 -0.46 0.65 0.52 -0.41 0.56 0.39
Mental 
Summary 
Score 
(MCS)
-0.45 0.39 0.49 -0.58 0.66 0.63 -0.59 0.42 0.57
EQ-5D
Index Score -0.51 1.00 0.39 -0.71 1.00 0.63 -0.53 1.00 0.39
VAS-
General 
Health
-0.35 0.39 1.00 -0.58 0.63 1.00 -0.46 0.39 1.00
1All correlations were significant at p < 0.001, unless otherwise noted. *p ≤ 0.05, **p ≤ 0.01, ns = non-significant.Health and Quality of Life Outcomes 2006, 4:71 http://www.hqlo.com/content/4/1/71
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responder was defined as a patient with a PASI75
response. A non-responder was a patient with <PASI 50,
since some of the secondary endpoints in the trial used
this cut-off. The results of these analyses are displayed in
Table 6. DLQI total scores for responders improved by
12.17 points, while scores of non-responders improved
by 1.77 points. This difference was statistically significant
(t = 9.0; p < 0.0001). All the PRO measures except for the
SF-36 Physical Functioning domain were responsive, as
defined by a statistically significant difference between
responders and non-responders. The DLQI was the most
responsive of the PRO measures, as evidenced by the size
of the t-statistic and the effect size. The responsiveness of
the EQ-5D index and VAS scores were generally the same
as several of the SF-36 domain scores.
While the estimates of responsiveness displayed in the last
two columns of Table 5 take into account the full range of
PASI change scores and their relationship to PRO change
scores, the responsiveness analysis in Table 6 places
patients in two categories – responders and non-respond-
ers. Table 7 defines four categories of responders: respond-
ers, defined as those with PASI improvements ≥ 75%;
"partial responders," those with PASI improvement 50–
74%, inclusively; "near responders," those with PASI
improvement 25–49%, inclusively; and non-responders,
Table 6: Change in PRO measures among responder1 groups
Change in Measure Mean Change Score for 
Responders (n = 66)
Mean Change Score for 
Non-Responders (n = 53)
Difference t-value P Value Effect Size
DLQI Total Score -12.17 (6.78) -1.77 (5.52) -10.39 9.0 <.0001 0.40
SF-36
Physical Functioning 9.12 (23.50) 3.52 (20.19) 5.59 1.4 0.1724 0.01
Role-Physical 20.08 (35.69) -5.19 (44.76) 25.26 3.4 0.0008 0.08
Bodily Pain 26.47 (27.40) 4.21 (22.74) 22.26 4.7 <.0001 0.15
General Health 8.87 (15.62) 1.47 (17.77) 7.39 2.4 0.0178 0.04
Vitality 13.01 (22.58) 1.13 (18.20) 11.87 3.1 0.0024 0.07
Social Functioning 21.59 (28.13) -2.59 (25.04) 24.19 4.9 <.0001 0.16
Role-Emotional 19.70 (32.54) -9.62 (36.95) 29.31 4.6 <.0001 0.14
Mental Health 14.55 (17.77) -0.38 (18.15) 14.92 4.5 <.0001 0.14
Physical Summary Score (PCS) 5.35 (9.67) 1.47 (9.08) 3.88 2.2 0.0287 0.03
Mental Summary Score (MCS) 8.03 (10.59) -2.03 (10.42) 10.06 5.1 <.0001 0.17
EQ-5D
Index Score 0.25 (0.30) 0.04 (0.26) 0.22 4.2 <.0001 0.12
VAS General Health 15.69 (18.96) 1.92 (23.24) 13.77 3.5 0.0006 0.09
1Responder is defined as PASI improvement ≥ 75%; non-responder is defined as PASI improvement <50%.
Table 5: Correlations1 between PROs and clinical endpoints at baseline and week 12, and change from baseline to week 12
Measure Baseline Week 12 Change
PASI PGA PASI PGA PASI PGA
DLQI Total Score 0.31 0.29 0.67 0.65 0.69 0.71
SF-36
Physical Functioning -0.32 -0.14 ns -0.28 -0.25** -0.38 -0.14 ns
Role-Physical -0.22** -0.14 ns -0.41 -0.37 -0.42 -0.31
Bodily Pain -0.36 -0.19* -0.47 -0.42 -0.60 -0.44
General Health -0.08 ns 0.05 ns -0.34 -0.33 -0.34 -0.24**
Vitality -0.15 ns -0.06 ns -0.37 -0.37 -0.38 -0.31
Social Functioning -0.23** -0.21** -0.46 -0.38 -0.44 -0.43
Role-Emotional -0.16 ns -0.06 ns -0.37 -0.29 -0.39 -0.36
Mental Health -0.17* -0.09 ns -0.46 -0.38 -0.43 -0.36
Physical Summary -0.28 -0.13 ns -0.35 -0.33 -0.45 -0.25**
Mental Summary -0.12 ns -0.08 ns -0.44 -0.36 -0.40 -0.42
EQ-5D
Index Score -0.40 -0.31 -0.60 -0.51 -0.57 -0.44
VAS-General Health -0.24** -0.09 ns -0.52 -0.43 -0.43 -0.38
PASI 1.00 0.59 1.00 0.83 1.00 0.75
1All correlations were significant at p < 0.001, unless otherwise noted. *p ≤ 0.05, ** p < 0.01, ns = non-significant.Health and Quality of Life Outcomes 2006, 4:71 http://www.hqlo.com/content/4/1/71
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with <PASI25. One-way analyses of variance were per-
formed among these groups for each of the PRO meas-
ures. As can be seen by the size of the f-statistics, the DLQI
was the most responsive of the PRO measures. In fact,
only the DLQI was able to demonstrate statistically signif-
icant differences between responders and partial respond-
ers based on post-hoc significance tests among the four
responder groups. These results for the DLQI total score
with respect to differences among responder groups were
similar to those reported previously in the literature,
except that the improvement in DLQI total scores dis-
played in Table 7 was larger for each of the responder
groups than for the equivalent responder groups
described by Shikiar and colleagues in a study of efalizu-
mab [28]. As was the case for the data displayed in Table
6, the responsiveness of the EQ-5D index and VAS scores
were generally the same as for most of the SF-36 scores.
Finally, both the SF-36 MCS and PCS scores were respon-
sive, but the MCS was substantially more responsive, indi-
cating that the impact of the disease was both physical
and mental, with the latter perhaps being more promi-
nent for this study population.
Estimates of Minimum Important Differences
There is no one best way to estimate the MID for a PRO
measure [21,34]. Table 8 contains three different anchor-
based methods for estimating the MID based on data
from this study. MID-1 contains the estimate obtained
from the scores from the "near-responders," shown as the
PASI 25-PASI 49 group in Table 7; MID-2 contains the
estimate corresponding to "partial responders" in the
same table 7. MID-3 corresponds to the difference
between non-responders for the PGA (defined as patients
who had no change in score or a decrease in score by one
point on this 7-point scale) and minimal responders for
this same measure (defined as patients who improved by
1 or 2 points). The distribution-based estimates, the SEM
and one-half the standard deviation of baseline scores are
also reported in Table 8.
Estimates for the DLQI MID ranged from 4.05 (for MID-
1) to 6.95 (for MID-2), while the SEM was 2.33 and one-
half standard deviation was 3.59. The MID results for the
SF-36 PCS ranged from 0.51 (for MID-3) to 3.91 (for
MID-1), with the SEM estimated as 2.71 and one-half
Table 7: PRO change scores corresponding to levels of PASI improvement
Change in 
Measure
PASI 
Improvement 
<25% (n = 31)
PASI 
Improvement 
25–49% (n = 22)
PASI 
Improvement 
50–74% (n = 21)
PASI 
Improvement 
≥75% (n = 66)
Overall F Value p Values1
DLQI Total 
Score
-0.16 (5.41) -4.05 (4.95) -6.95 (5.71) -12.17 (6.78) 30.4*** 2**,3***,5***,6*
SF-36
Physical 
Functioning
2.15 (17.67) 5.45 (23.60) 0.02 (22.36) 9.12 (23.50) 1.2
Role-Physical -11.29 (39.18) 3.41 (51.35) 14.29 (31.20) 20.08 (35.69) 4.9** 3**
Bodily Pain -1.03 (21.42) 11.59 (22.96) 16.76 (22.74) 26.47 (27.40) 9.0*** 3***
General Health -0.61 (17.33) 4.41 (18.37) 9.19 (11.29) 8.87 (15.62) 2.8*
Vitality -1.45 (16.29) 4.77 (20.44) 6.90 (17.43) 13.01 (22.58) 3.8* 3*
Social 
Functioning
-3.23 (23.71) -1.70 (27.36) 13.10 (17.44) 21.59 (28.13) 8.7*** 3***, 5**
Role-Emotional -11.11 (36.44) -7.58 (38.40) 17.46 (34.35) 19.70 (32.54) 7.6*** 2*, 3**, 5*
Mental Health -0.77 (18.08) 0.18 (18.66) 9.52 (13.53) 14.55 (17.77) 7.2*** 3**,5*
Physical 
Summary
-0.31 (7.18) 3.91 (10.88) 2.57 (7.78) 5.35 (9.67) 2.7*
Mental 
Summary
-2.19 (9.86) -1.82 (11.38) 6.05 (6.90) 8.03 (10.59) 9.9*** 2*, 3***, 5**
EQ-5D
Index Score -0.01 (0.26) 0.10 (0.24) 0.20 (0.21) 0.25 (0.30) 7.1*** 3***
VAS General 
Health
0.58 (24.31) 3.82 (22.07) 8.43 (11.24) 15.69 (18.96) 4.8** 3**
Mean PASI 
Improvement2
0.94 (4.07) -6.24 (2.99) -8.94 (3.47) -14.33 (7.65)
1Pairwise comparisons between means were performed using Scheffe's test adjusting for multiple comparisons. 1 = improvement <25% vs. 
improvement 25–49%, 2 = improvement <25% vs. improvement 50–74%, 3 = improvement <25% vs. improvement ≥ 75%, 4 = improvement 25–
49% vs. improvement 50–74%, 5 = improve 25–49% vs. improvement ≥ 75%, and 6 = improvement 50–74% vs. improvement ≥ 75%. *p < 0.05, **p 
< 0.01, ***p < 0.001.
2Negative change scores indicate improvement.Health and Quality of Life Outcomes 2006, 4:71 http://www.hqlo.com/content/4/1/71
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standard deviation estimates as 5.12. For the MCS, the
MID estimates included a decrease of 1.82 points based
on a PASI improvement of 25–49%, but the other two
MIDs were 6.05 and 6.61, respectively. The SEM for the
MCS was 3.89 and one-half standard deviation was 5.61.
Consistent with the MCS findings, decreases were
observed for the Role-Emotional and Social Functioning
domains for the MID-1 definition. The differences
between non-responders and minimal responders ranged
from 4.90 for Mental Health to 24.71 for Social Function-
ing (Table 8). The results for the EQ-5D index score dem-
onstrated an MID ranging from 0.09 (for MID-3) to 0.20
(for MID-2). For the EQ-5D VAS, the available estimates
ranged from 3.82 (MID-1) to 8.43 (MID-3).
Discussion
A Phase II randomized clinical trial of adalimumab in
moderate to severe plaque psoriasis provided the oppor-
tunity to evaluate the validity and responsiveness to clini-
cal change of three PRO assessment instruments – one
dermatology-specific instrument and two general health
status instruments – all used as endpoints in the study. All
analyses were performed on a blinded basis, since the
main focus of these secondary analyses was on the psy-
chometric qualities of the PRO instruments.
Although developed for a general population with derma-
tologic diseases, the DLQI has most frequently been
applied to patients with plaque psoriasis [27]. More
recently, the DLQI has been used as an endpoint in clini-
cal trials involving the newer class of biologics for treat-
ment of moderate to severe psoriasis, including alefacept
[6,7], etanercept [9,10], and efalizumab [8,11]. The
present study further establishes the reliability and valid-
ity of the DLQI and its responsiveness to change in the
clinical status of patients over the course of a 12-week
clinical trial, confirming previous findings [28]. Changes
in the DLQI total score demonstrated significant and size-
able correlations with independently obtained physician-
assessed changes in the clinical statuses of patients. This
indicates that the alleviation of psoriatic signs, as deter-
mined by clinical assessments, results in significant and
marked improvement in dermatologic-related functional
limitations and quality of life in patients with moderate to
severe plaque psoriasis. Based on this study, the DLQI is a
psychometrically sound and responsive measure of pso-
riasis-specific outcomes that captures more comprehen-
sively the impact of clinical signs and symptoms on
patient well-being.
Data were also used to derive estimates of the MID of the
DLQI. Although the MID is defined as the smallest differ-
ence that a patient would perceive as beneficial, there were
no patient-based assessments of change in this study.
Hence, lacking a patient-based anchor, the data do not
provide the basis for determining the smallest score that a
patient would perceive as beneficial. We used both the
PASI and the PGA, as well as two distributional
approaches to derive estimates of the MID of the DLQI.
These estimates ranged from 2.33–6.95. However, we
believe that the PASI 50 is too conservative for estimating
the minimum change that patients will find beneficial.
Table 8: Estimates of MCID for PRO measures
Change in Measure MID-1: PASI 
Improvement 25–49%
MID-2: PASI 
Improvement 50–74%
MID-3: Difference Between 
Non-Responders (n = 34) 
and Minimal Responders (n 
= 41) on PGA
SEM 0.5 SD
DLQI Total Score -4.05 (4.95) -6.95 (5.71) -5.69 2.33 3.59
SF-36
Physical Functioning1 N/A N/A N/A N/A N/A
Role-Physical 3.41 (51.35) 14.29 (31.20) 10.51 15.02 18.78
Bodily Pain 11.59 (22.96) 16.76 (22.74) 9.05 10.76 12.69
General Health 4.41 (18.37) 9.19 (11.29) 4.97 9.67 10.31
Vitality 4.77 (20.44) 6.90 (17.43) 6.54 8.22 11.40
Social Functioning -1.70 (27.36) 13.10 (17.44) 13.62 10.67 13.78
Role-Emotional -7.58 (38.40) 17.46 (34.35) 24.71 14.59 17.70
Mental Health 0.18 (18.66) 9.52 (13.53) 4.90 6.10 9.65
Physical Summary Score (PCS) 3.91 (10.88) 2.57 (7.78) 0.51 2.71 5.12
Mental Summary Score (MCS) -1.82 (11.38) 6.05 (6.90) 6.61 3.89 5.61
EQ-5D
Index Score 0.10 (0.24) 0.20 (0.21) 0.09 0.22 0.14
VAS-General Health 3.82 (22.07) 8.43 (11.24) 4.59 N/A 10.34
Note: MID-1 corresponds to the score for the PASI 25–49 group; MID-2 corresponds to the score for the PASI50-74; for MID-3 and MID-4, 
reliability estimates for computing SEM were obtained from the data in this study for the DLQI and from estimates found in the literature for the 
SF-36 and EQ-5D.
1MID estimates are not provided for the SF-36 Physical Function domain since there were not significant differences among responder groups.Health and Quality of Life Outcomes 2006, 4:71 http://www.hqlo.com/content/4/1/71
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Therefore, we believe the estimate based on PASI
improvement of 25–49% or between non-responders and
minimal responders provide better estimates of MID.
Therefore, the results indicate that the MID is in the range
of approximately 2.3–5.7, which is slightly higher than
the range of estimates derived from Shikiar et al. [28] in
an analysis of two clinical trials involving another psoria-
sis therapy. The distributional approaches resulted in the
lowest estimates of MID for the DLQI, but it should be
noted that the distributional approach to estimating the
MID is considered supportive of the anchor-based meth-
ods [22,35]. For example, the one-half standard deviation
estimate is certainly clinically meaningful, but is likely not
a minimum magnitude of change. Finally, the range of
estimates incorporates another previous estimate of the
MID of the DLQI of 5.0 [36].
Two general PRO measures were used in this study. In
general, the EQ-5D index and VAS scores demonstrated
higher correlations than the SF-36 scale scores with the
clinical endpoints (Table 5). However, the responsiveness
of these two EQ-5D scores was generally the same as the
responsiveness of most of the SF-36 scores. Nonetheless,
this study demonstrated that the EQ-5D performs at least
as well as the SF-36 as a non-dermatologic specific PRO
measure for this sample of moderate to severe psoriatic
patients.
Although most of the SF-36 scores showed improvements
associated with clinical outcomes, the MCS, Social Func-
tioning, and Role-Emotional domain scores demon-
strated decreases in the PASI 25–49% group. These
findings may have been driven by several outliers and the
relatively small sample size for this group. Alternatively,
given that Bodily Pain and other physical domains may be
more related to the signs and symptoms of psoriasis than
Role-Limitations and Social Functioning, small improve-
ments in PASI scores may not be directly associated with
changes in these PRO domains. That is, larger changes in
clinical outcomes may be needed to significantly impact
the areas of physical function and well-being. This idea
seems to be supported by the observed changes in the
PASI 50–74% and other analyses. However, the SF-36
domain and summary scores demonstrated consistently
reasonable validity and were correlated with clinical end-
points and DLQI scores.
The SF-36 PCS and MCS scores demonstrated good evi-
dence of validity and responsiveness in this sample of
patients with moderate to severe plaque psoriasis. There
were demonstrable associations between changes in PASI
score categories and changes in PCS scores, with the larg-
est improvements seen in the PASI75 responder groups.
The MID estimates for the PCS were in the range of 0.51–
3.91, with the best estimate at approximately 2.5 points.
The SEM estimate (2.71) also supports this range of MID
values for the PCS. These results are consistent with previ-
ous research on the PCS scores in rheumatoid arthritis and
other chronic diseases [29, 37]. The MID findings for the
MCS were somewhat weaker, but there is evidence that a
change of 4–6 points is certainly clinically meaningful.
The MID for the EQ-5D index score was in the range of
0.09–0.22.
Given the impact of psoriasis on the functional ability of
patients the importance attached to assessing physical
function in psoriasis patients, the results of the present
study provide positive support for the use of a dermatol-
ogy-specific health-related PRO measure, the DLQI, in the
assessment of psoriasis and responses to treatment. In
addition, the correlation of SF-36 and DLQI indicates that
disease-related changes in the SF-36 are largely dependent
on two specific domains, Bodily Pain and Social Func-
tioning. It appears that the DLQI total score, as a single
index score, adequately captures the functional and psy-
chosocial impact of moderate to severe plaque psoriasis.
Further, the DLQI does so in a way that is substantially
more responsive than the general health-related quality of
life measures used to assess changes in patients' underly-
ing clinical statuses. The importance of the DLQI in meas-
uring psoriasis patients' disease statuses, both at baseline
and after treatment, is underlined by recent UK guidelines
that recommend the DLQI serve both as an indicator of
biologic therapy need and adequate treatment response
[14].
There were several limitations to the present analysis. The
first relates to sample size and selection. The sample was
limited to those meeting the inclusion/exclusion criteria if
this Phase II clinical trial. Since this was a Phase II study,
the sample size was smaller (N = 147) than typical Phase
III studies involving moderate to severe psoriasis, thereby
requiring even one to use even greater caution in extrapo-
lating the results of this analysis. Other applications of the
PRO instruments (e.g., other clinical settings or settings
including non-biologic treatments) might not involve the
same exclusions. Therefore, generalizability of these
results may not be applicable to all clinical settings. Sec-
ond, the DLQI is not the only dermatology-specific instru-
ment to assess the impact of psoriasis on physical
function and psychosocial factors. Other instruments
have been developed [38, 39], but have not been used as
frequently as the DLQI in psoriasis trials. Nonetheless,
results reported here do not indicate whether the DLQI
has relative advantages or disadvantages to these instru-
ments. Finally, given that the MID denotes the minimum
change that a patient would find beneficial, anchoring the
estimates of MID to patient assessments of severity or
change would prove useful, and the current Phase II trial
did not include such assessments.Health and Quality of Life Outcomes 2006, 4:71 http://www.hqlo.com/content/4/1/71
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Conclusion
The findings of this study highlight the importance of cap-
turing PRO measures in clinical trials of moderate to
severe plaque psoriasis. This analysis provides additional
evidence supporting the psychometric qualities and
responsiveness of the DLQI as a disease-specific measure
of PROs in psoriasis. The DLQI MID was determined as
ranging from 2.3–5.7 points. While the DLQI provides the
most reliable measure of clinical change, the data from
this study demonstrate that the SF-36 and EQ-5D per-
formed well as general measures of health status out-
comes. While the SF-36 has been used in previous studies
comparing psoriasis treatments [6,7,30], to date, there
have been few applications of the EQ-5D in clinical trials
of patients with moderate to severe plaque psoriasis. The
results of this study indicate that these two instruments
should be considered as a general health outcome meas-
ure in future clinical trials.
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